stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Return on equity
NeoGenomics, Inc.'s return on equity over the twelve months to 30 September 2026 was −3.94%, up 8.5 percentage points from fiscal 2025 (−12.4%). Over the past ten years it has ranged from −16.5% (fiscal 2016) to 2.47% (fiscal 2018); the current reading is higher than 27% of that period. That is below the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −12.4% | (3.88) |
| FY2024 | −8.54% | 0.53 |
| FY2023 | −9.07% | 4.63 |
| FY2022 | −13.7% | (12.77) |
| FY2021 | −0.93% | (1.62) |
| FY2020 | 0.69% | (1.24) |
| FY2019 | 1.93% | (0.54) |
| FY2018 | 2.47% | 8.99 |
| FY2017 | −6.52% | 9.99 |
| FY2016 | −16.5% | (14.54) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CDNA CareDx, Inc. compare | 33.0% |
| FRNM Freenome, Inc compare | 17.8% |
| VCYT Veracyte, Inc. compare | 9.43% |
| NEO NeoGenomics, Inc. | −3.94% |
| CSTL Castle Biosciences, Inc. compare | −4.87% |
| OPK OPKO Health, Inc. compare | −12.2% |
| ADPT Adaptive Biotechnologies Corporation compare | −36.3% |
| WGS GeneDx Holdings Corp. compare | −40.8% |
| PSNL Personalis, Inc. compare | −62.1% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement